David Holtzman
David Holtzman
Verified email at
Cited by
Cited by
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic …
MS Albert, ST DeKosky, D Dickson, B Dubois, HH Feldman, NC Fox, ...
Alzheimer's & dementia 7 (3), 270-279, 2011
Inflammation and Alzheimer’s disease
H Akiyama, S Barger, S Barnum, B Bradt, J Bauer, GM Cole, NR Cooper, ...
Neurobiology of aging 21 (3), 383-421, 2000
NIA-AA research framework: toward a biological definition of Alzheimer's disease
CR Jack Jr, DA Bennett, K Blennow, MC Carrillo, B Dunn, SB Haeberlein, ...
Alzheimer's & Dementia 14 (4), 535-562, 2018
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
RJ Bateman, C Xiong, TLS Benzinger, AM Fagan, A Goate, NC Fox, ...
N Engl J Med 367, 795-804, 2012
National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards
V Hachinski, C Iadecola, RC Petersen, MM Breteler, DL Nyenhuis, ...
Stroke 37 (9), 2220-2241, 2006
The role of apolipoprotein E in Alzheimer's disease
J Kim, JM Basak, DM Holtzman
Neuron 63 (3), 287-303, 2009
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos, KR Bales, DJ Cummins, JC Dodart, SM Paul, DM Holtzman
Proceedings of the National Academy of Sciences 98 (15), 8850-8855, 2001
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
M Shibata, S Yamada, SR Kumar, M Calero, J Bading, B Frangione, ...
The Journal of clinical investigation 106 (12), 1489-1499, 2000
Alzheimer’s disease: the challenge of the second century
DM Holtzman, JC Morris, AM Goate
Science translational medicine 3 (77), 77sr1-77sr1, 2011
The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases
S Krasemann, C Madore, R Cialic, C Baufeld, N Calcagno, R El Fatimy, ...
Immunity 47 (3), 566-581. e9, 2017
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan, MA Mintun, RH Mach, SY Lee, CS Dence, AR Shah, ...
Annals of neurology 59 (3), 512-519, 2006
Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle
JE Kang, MM Lim, RJ Bateman, JJ Lee, LP Smyth, JR Cirrito, N Fujiki, ...
Science 326 (5955), 1005-1007, 2009
Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria
B Dubois, H Hampel, HH Feldman, P Scheltens, P Aisen, S Andrieu, ...
Alzheimer's & Dementia 12 (3), 292-323, 2016
Synaptic activity regulates interstitial fluid amyloid-β levels in vivo
JR Cirrito, KA Yamada, MB Finn, RS Sloviter, KR Bales, PC May, ...
Neuron 48 (6), 913-922, 2005
TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model
Y Wang, M Cella, K Mallinson, JD Ulrich, KL Young, ML Robinette, ...
Cell 160 (6), 1061-1071, 2015
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance
JM Castellano, J Kim, FR Stewart, H Jiang, RB DeMattos, BW Patterson, ...
Science translational medicine 3 (89), 89ra57-89ra57, 2011
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart, KR Bales, KS Gannon, SJ Greene, RB DeMattos, C Mathis, ...
Nature neuroscience 5 (5), 452-457, 2002
Alzheimer disease: an update on pathobiology and treatment strategies
JM Long, DM Holtzman
Cell 179 (2), 312-339, 2019
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
RD Bell, EA Winkler, I Singh, AP Sagare, R Deane, Z Wu, DM Holtzman, ...
Nature 485 (7399), 512-516, 2012
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
M Meyer-Luehmann, TL Spires-Jones, C Prada, M Garcia-Alloza, ...
Nature 451 (7179), 720-724, 2008
The system can't perform the operation now. Try again later.
Articles 1–20